Humaid Al-Shamsi: Honored to Join Nexomic as Chairman to Help Advance AI-Driven Precision Oncology

Mission

Nexomic, an Ireland-based biotechnology company, focuses on advancing AI-driven biomarker discovery and multi-omic precision oncology. The mission is to transform complex genomic, transcriptomic, proteomic, and clinical data into actionable insights that can help accelerate drug discovery, enrich clinical trials, and support more personalized cancer care.

Team

Nexomic is led by an exceptional team of more than 20 bright minds, including PhDs, scientists, AI experts, bioinformaticians, and an advisory board of oncology leaders. The team works together to push the boundaries of cancer research.

Humaid Al-Shamsi's Role

As the Chairman of Nexomic, Humaid Al-Shamsi brings his deep clinical expertise as an oncologist, researcher, and healthcare leader to the mission. He believes the future of cancer care will be shaped by the integration of deep clinical expertise with powerful AI and multi-omic intelligence. Nexomic's ultimate ambition is to contribute meaningfully to the global mission to cure cancer.

Future Vision

Humaid Al-Shamsi is honored to join this journey and help build a platform that may redefine biomarker discovery, clinical trial design, and precision oncology.